COMMUNIQUÉS West-GlobeNewswire

-
Rule 2.9 Announcement
23/11/2018 -
Curetis Announces Financial Results for the First Nine Months of 2018
23/11/2018 -
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
23/11/2018 -
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
23/11/2018 -
Curetis Accelerates 510(k) Submission Preparation for Unyvero LRT in BAL Specimen Based on Positive FDA Feedback
23/11/2018 -
Sensorion Enters Into Exclusive Negotiations with Pasteur Institute for Hearing Loss Gene Therapy Programs
23/11/2018 -
Nova Leap Health Corp. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
23/11/2018 -
North Bud Farms Provides Corporate Update
22/11/2018 -
Agility Health Announces Demand by Lender and Notice of Intention to Enforce Security
22/11/2018 -
Canadian company proves exercise is a miracle drug
22/11/2018 -
Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza® in Japanese people with type 2 diabetes
22/11/2018 -
Canopy Rivers Secures International Joint Venture Rights and Accelerates Development at PharmHouse
22/11/2018 -
Aurora Spine Corporation Files Condensed Consolidated Financial Statements for the Three and Nine Months Ended September 30, 2018
22/11/2018 -
Canada House Grants Common Shares to Senior Executive Management
22/11/2018 -
Emerald Health Therapeutics Appoints Agro-Biotech President
22/11/2018 -
Emerald Health Therapeutics nomme le président d’Agro-Biotech
22/11/2018 -
Tetra Bio-Pharma Seeks Solutions for Second Hand Smoke From Cannabis
22/11/2018 -
The Management Board of JSC Olainfarm: shareholders chose stability and development by their voting
22/11/2018 -
Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union
22/11/2018
Pages